Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Matt Costa is our new Professor of Orthopaedic Trauma.

The Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) is pleased to welcome Professor Matt Costa to the department, joining from 11 May 2015 as Professor of Orthopaedic Trauma Surgery.

Matt is an internationally recognised clinical academic in orthopaedic trauma , as well as having his own clinical practice in trauma surgery. He joins us from the Warwick Clinical Trials Unit, where until recently he was Professor of Trauma and Orthopaedics.

Matt’s research interest is in clinical and cost effectiveness of musculoskeletal interventions, as well as clinical trials and trial design.

Speaking of his appointment, Professor Costa said: “I’m very excited to be joining the team at NDORMS. Musculoskeletal trauma is a huge issue for patients, the NHS and society more broadly. There are so many areas where we can improve patient care and there is no where in the world better placed to address this need than Oxford. I can’t wait to start at NDORMS and look forward to working with the world-leading academics at the University and the world-leading surgeons at the John Radcliffe Hospital”.

Professor Andrew Carr, Head of NDORMS welcomed Professor Costa and said: "I am delighted that Professor Matt Costa is joining the department. He has an international reputation in surgical trials of trauma and will add significantly to research in this area”.

Similar stories

New centre aims to help companies conduct more efficient trials

Botnar Main Trials

A new clinical therapeutics centre has been set up by the University of Oxford to help life sciences companies identify interventions that have the greatest potential to deliver patient benefit, and so bring down the cost of early phase clinical trials.

Cognitive–behavioural therapy consistently improves quality of life

Main Rehabilitation and self-management Research

A meta-review of the available research into cognitive behavioural therapy reveals it consistently improves health-related quality of life across different medical conditions and demographic populations.

Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders

Main Research

The University of Oxford has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Versus Arthritis Foundation Fellowship awarded to Dr Kristina Zec

Awards Main

Dr Kristina Zec has been awarded a Versus Arthritis Foundation Fellowship to investigate the role of products of lipid oxidation produced by synovial macrophages in triggering articular inflammation.

Study reveals the safety of bisphosphonates in chronic kidney disease

Main

The results of an observational study published in JMBR and funded by the Health Technology Assessment Programme shows that bisphosphonate use is associated with a greater risk of chronic kidney disease progression.

WHiTE Four trial results published

Hip Main OCTRU Orthopaedics and trauma Research Trauma

The results of the WHiTE Four clinical trial for the treatment of fragility hip fractures have been published in The Bone and Joint Journal.